In ovarian cancer trials, many patients in the placebo group later receive a PARP inhibitor. This crossover "pollutes" the data, making it difficult to prove a statistically significant overall survival benefit for frontline PARP maintenance, despite its clear effectiveness.

The trial allowed patients in the placebo group to receive retifanlimab upon progression (crossover). This common design dilutes the observed overall survival difference. While initial results were not statistically significant, updated data revealed a clinically meaningful 10.6-month median OS improvement.

The Podium 303 study's design allowed placebo patients to receive retafanilumab upon progression. This crossover contaminated the control arm, likely diluting the true overall survival benefit and making the first-line combination therapy appear less statistically significant than it actually is.

In trials like ASCENT-4, where over 80% of the control arm received sacituzumab govitecan upon progression, the true overall survival (OS) benefit is obscured. This makes progression-free survival (PFS) a more reliable endpoint for evaluating the drug's first-line efficacy.

The AscentO3 trial lacked an overall survival benefit for its primary endpoint because its design ethically allowed patients on the chemotherapy arm to receive sacituzumab govitecan upon progression. This 'crossover' improves care for the control group but makes it statistically difficult to demonstrate a first-line survival advantage.

In pivotal ADC trials like ASCENT-03 and 04, over 80% of patients in the control (chemotherapy) arm received the ADC upon progression. This high crossover rate makes interpreting overall survival (OS) data difficult, as the control group's outcomes are artificially improved by subsequent access to the novel drug.

In the ASCENT-07 trial, investigators may have prematurely switched patients from the standard chemotherapy arm to superior, commercially available ADCs at the first hint of progression. This real-world practice can mask an experimental drug's true benefit on progression-free survival.

The trial allowed over 75% of patients in the control group to receive Rucaparib after their cancer progressed. While ethical, this high crossover rate effectively turned the study into an "upfront vs. delayed PARP inhibitor" comparison, which is the primary reason no significant overall survival difference was observed.

The KEYNOTE-177 trial allowed patients on the chemotherapy arm to cross over to pembrolizumab upon progression. Despite this, pembrolizumab showed a significant survival advantage, implying the actual benefit of using immunotherapy first-line is even greater than what the data shows.